Helper T cells point the way to specific immunotherapy for autoimmune disease

Andrew M Hall, Mark A Vickers, Robert N Barker, Lars P Erwig

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Autoimmune haemolytic anaemia (AIHA) is characterised by the production of autoantibodies that target determinants on red blood cells. Current treatments rely on generalised immunosupression or cytotoxic treatments that may have potentially harmful side effects. Whilst the underlying cause of disease remains unknown, recent advances in our understanding of CD4+ helper T cell (Th) subsets that drive and control the autoimmune response have important implications for the development of novel immunotherapy. The effector arm of the adaptive immune response is now known to include at least three Th subsets: Th1, Th2 and the recently described Th17. In human AIHA, the targets of the autoimmune response in most patients, the Rhesus (Rh) proteins, have been identified and sequenced, providing the opportunity to study antigen specific responses. The effector Th response is dominated by Th1 cells that are under the control of IL-10 dependent regulatory cells (Tr1). These Th1 responses can be suppressed, with synthetic peptides that are recognised by the Tr1 cells. Such specificity would provide an extremely potent tool in the treatment of autoimmune disease. This review discusses the recent advances in our understanding of helper T cell subsets and the implications for the development of specific immunotherapy in autoimmune disease, using the well characterised responses in AIHA as an example.
Original languageEnglish
Pages (from-to)159-166
Number of pages8
JournalCardiovascular & Hematological Disorders - Drug Targets
Volume9
Issue number3
DOIs
Publication statusPublished - 1 Sep 2009

Fingerprint

Autoimmune Hemolytic Anemia
Helper-Inducer T-Lymphocytes
Immunotherapy
Autoimmune Diseases
T-Lymphocyte Subsets
Regulatory T-Lymphocytes
Autoimmunity
Th1 Cells
Adaptive Immunity
Interleukin-10
Autoantibodies
Therapeutics
Erythrocytes
Antigens
Peptides
Proteins

Keywords

  • autoimmune
  • autoimmune haemolytic anaemia
  • peptide therapy
  • helper T cell
  • regulatory T cell
  • cytokine

Cite this

Helper T cells point the way to specific immunotherapy for autoimmune disease. / Hall, Andrew M; Vickers, Mark A; Barker, Robert N; Erwig, Lars P.

In: Cardiovascular & Hematological Disorders - Drug Targets, Vol. 9, No. 3, 01.09.2009, p. 159-166.

Research output: Contribution to journalArticle

@article{8683d216574046988896bb122e9457bf,
title = "Helper T cells point the way to specific immunotherapy for autoimmune disease",
abstract = "Autoimmune haemolytic anaemia (AIHA) is characterised by the production of autoantibodies that target determinants on red blood cells. Current treatments rely on generalised immunosupression or cytotoxic treatments that may have potentially harmful side effects. Whilst the underlying cause of disease remains unknown, recent advances in our understanding of CD4+ helper T cell (Th) subsets that drive and control the autoimmune response have important implications for the development of novel immunotherapy. The effector arm of the adaptive immune response is now known to include at least three Th subsets: Th1, Th2 and the recently described Th17. In human AIHA, the targets of the autoimmune response in most patients, the Rhesus (Rh) proteins, have been identified and sequenced, providing the opportunity to study antigen specific responses. The effector Th response is dominated by Th1 cells that are under the control of IL-10 dependent regulatory cells (Tr1). These Th1 responses can be suppressed, with synthetic peptides that are recognised by the Tr1 cells. Such specificity would provide an extremely potent tool in the treatment of autoimmune disease. This review discusses the recent advances in our understanding of helper T cell subsets and the implications for the development of specific immunotherapy in autoimmune disease, using the well characterised responses in AIHA as an example.",
keywords = "autoimmune, autoimmune haemolytic anaemia, peptide therapy, helper T cell, regulatory T cell, cytokine",
author = "Hall, {Andrew M} and Vickers, {Mark A} and Barker, {Robert N} and Erwig, {Lars P}",
year = "2009",
month = "9",
day = "1",
doi = "10.2174/187152909789007043",
language = "English",
volume = "9",
pages = "159--166",
journal = "Cardiovascular & Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Helper T cells point the way to specific immunotherapy for autoimmune disease

AU - Hall, Andrew M

AU - Vickers, Mark A

AU - Barker, Robert N

AU - Erwig, Lars P

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Autoimmune haemolytic anaemia (AIHA) is characterised by the production of autoantibodies that target determinants on red blood cells. Current treatments rely on generalised immunosupression or cytotoxic treatments that may have potentially harmful side effects. Whilst the underlying cause of disease remains unknown, recent advances in our understanding of CD4+ helper T cell (Th) subsets that drive and control the autoimmune response have important implications for the development of novel immunotherapy. The effector arm of the adaptive immune response is now known to include at least three Th subsets: Th1, Th2 and the recently described Th17. In human AIHA, the targets of the autoimmune response in most patients, the Rhesus (Rh) proteins, have been identified and sequenced, providing the opportunity to study antigen specific responses. The effector Th response is dominated by Th1 cells that are under the control of IL-10 dependent regulatory cells (Tr1). These Th1 responses can be suppressed, with synthetic peptides that are recognised by the Tr1 cells. Such specificity would provide an extremely potent tool in the treatment of autoimmune disease. This review discusses the recent advances in our understanding of helper T cell subsets and the implications for the development of specific immunotherapy in autoimmune disease, using the well characterised responses in AIHA as an example.

AB - Autoimmune haemolytic anaemia (AIHA) is characterised by the production of autoantibodies that target determinants on red blood cells. Current treatments rely on generalised immunosupression or cytotoxic treatments that may have potentially harmful side effects. Whilst the underlying cause of disease remains unknown, recent advances in our understanding of CD4+ helper T cell (Th) subsets that drive and control the autoimmune response have important implications for the development of novel immunotherapy. The effector arm of the adaptive immune response is now known to include at least three Th subsets: Th1, Th2 and the recently described Th17. In human AIHA, the targets of the autoimmune response in most patients, the Rhesus (Rh) proteins, have been identified and sequenced, providing the opportunity to study antigen specific responses. The effector Th response is dominated by Th1 cells that are under the control of IL-10 dependent regulatory cells (Tr1). These Th1 responses can be suppressed, with synthetic peptides that are recognised by the Tr1 cells. Such specificity would provide an extremely potent tool in the treatment of autoimmune disease. This review discusses the recent advances in our understanding of helper T cell subsets and the implications for the development of specific immunotherapy in autoimmune disease, using the well characterised responses in AIHA as an example.

KW - autoimmune

KW - autoimmune haemolytic anaemia

KW - peptide therapy

KW - helper T cell

KW - regulatory T cell

KW - cytokine

U2 - 10.2174/187152909789007043

DO - 10.2174/187152909789007043

M3 - Article

C2 - 19534656

VL - 9

SP - 159

EP - 166

JO - Cardiovascular & Hematological Disorders - Drug Targets

JF - Cardiovascular & Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 3

ER -